Glycosylation of serum proteins in inflammatory diseases

Disease Markers

Volumn 25, Issue 4-5, 2008, Pages 267-278

  Gornik, Olga ^a   Lauc, Gordan ^a,b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Glycosylation; Inflammatory diseases; Pancreatitis; Rheumatoid arthritis; Sepsis; Serum proteins; Systemic lupus erythematosus

Indexed keywords

ALPHA 2 MACROGLOBULIN; C REACTIVE PROTEIN; GLYCAN; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OROSOMUCOID; PLASMA PROTEIN; TRANSFERRIN;

ANALYTIC METHOD; BURN; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INFLAMMATORY DISEASE; INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 58149391280     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/493289     Document Type: Review

References (102)

1. R.S. Cotran, Robbins pathologic basis of disease, 5th edition, 1994, Philadelphia: W.B. Saunders Co.
2. C. Gabay and I. Kushner, Acute-phase proteins and other systemic responses to inflammation, N Engl J Med 340 (1999), 448-454.
3. A. Varki et al., Essentials of glycobiology, C.S. Harbor, ed., 1999, New York: Cold Spring Harbor Laboratory Press.
4. J. Alper, Searching for medicine's sweet spot, Science 291 (2001), 2338-2343.
5. M. Bevilacqua, E. Butcher, B. Furie, B. Furie, M. Gallatin, M. Gimbrone, J. Harlan, K. Kishimoto, L. Lasky, R. McEver et al., Selectins: a family of adhesion receptors, Cell 67 (1991), 233.
6. S.R. Barthel, J.D. Gavino, L. Descheny and C.J. Dimitroff, Targeting selectins and selectin ligands in inflammation and cancer, Expert Opin Ther Targets 11 (2007), 1473-1491.
7. K. Ohtsubo and J.D. Marth, Glycosylation in cellular mechanisms of health and disease, Cell 126 (2006), 855-867.
8. G. Lauc, Sweet secret of the multicellular life, Biochim Biophys Acta 1760 (2006), 525-526.
9. R.T. Lee, G. Lauc, and Y.C. Lee, Glycoproteomics: protein modifications for versatile functions. Meeting on glycoproteomics, EMBO Rep 6(2005), 1018-22.
10. R.G. Spiro, Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds, Glycobiology 12 (2002), 43R-56R.
11. J. Axford, The impact of glycobiology on medicine, Trends Immunol 22 (2001), 237-239.
12. G.A. Turner, N-glycosylation of serum proteins in disease and its investigation using lectins, Clin Chim Acta 208 (1992), 149-171.
13. K. Schmid, R.B. Nimerg, A. Kimura, H. Yamaguchi and J.P. Binette, The carbohydrate units of human plasma alpha1-acid glycoprotein, Biochim Biophys Acta 492 (1977), 291-302.
14. H. Yoshima, A. Matsumoto, T. Mizuochi, T. Kawasaki and A. Kobata, Comparative study of the carbohydrate moieties of rat and human plasma alpha 1-acid glycoproteins, J Biol Chem 256 (1981), 8476-8484.
15. Y. Kuroda, A. Shibukawa and T. Nakagawa, Drug binding analysis of human alpha 1-acid glycoprotein using capillary electrophoresis, Yakugaku Zasshi 123 (2003), 781-788.
16. E.C. Brinkman-van der Linden, P.F. de Haan, E.C. Havenaar and W. van Dijk, Inflammation-induced expression of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent on alpha1-antichymotrypsin and haptoglobin, Glycoconj J 15 (1998), 177-182.
17. K. Higai, Y. Aoki, Y. Azuma and K. Matsumoto, Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation, Biochim Biophys Acta 1725 (2005), 128-135.
18. K. Higai, Y. Azuma, Y. Aoki and K. Matsumoto, Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus, Clin Chim Acta 329 (2003), 117-125.
19. D.C. Poland, C.G. Schalkwijk, C.D. Stehouwer, C.A. Koeleman, B. van het Hofand W. van Dijk, Increased alpha3-fucosylation of alpha1-acid glycoprotein in Type I diabetic patients is related to vascular function, Glycoconj J 18 (2001), 261-268.
20. M.F. Bierhuizen, M. De Wit, C.A. Govers, W. Ferwerda, C. Koeleman, O. Pos and W. Van Dijk, Glycosylation of three molecular forms of human alpha 1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of di-, tri-, and tetraantennary glycans and the degree of sialylation, Eur J Biochem 175 (1988), 387-394.
21. T.W. De Graaf, M.E. Van der Stelt, M.G. Anbergen and W. van Dijk, Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera, J Exp Med 177 (1993), 657-666.
22. A. Mackiewicz, M.A. Khan, T.L. Reynolds, S. van der Linden and I. Kushner, Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing spondylitis, Ann Rheum Dis 48 (1989), 99-103.
23. A. Mackiewicz, R. Marcinkowska-Pieta, S. Ballou, S. Mackiewicz and I. Kushner, Microheterogeneity of alpha 1-acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosus, Arthritis Rheum 30 (1987), 513-518.
24. A.J. Bleasby, J.C. Knowles and N.J. Cooke, Microheterogeneity of alpha 1-acid glycoprotein: lack of discrimination between benign and malignant inflammatory disease of the lung, Clin Chim Acta 150 (1985), 231-235.
25. A. Mackiewicz, T. Pawlowski, A. Mackiewicz-Pawlowska, K. Wiktorowicz and S. Mackiewicz, Microheterogeneity forms of alpha 1-acid glycoprotein as indicators of rheumatoid arthritis activity, Clin Chim Acta 163 (1987), 185-190.
26. K. Fassbender, W. Zimmerli, R. Kissling, M. Sobieska, A. Aeschlimann, M. Kellner and W. Muller, Glycosylation of alpha 1-acid glycoprotein in relation to duration of disease in acute and chronic infection and inflammation, Clin Chim Acta 203 (1991), 315-327.
27. O. Pos, M.E. van der Stelt, G.J. Wolbink, M.W. Nijsten, G.L. van der Tempel and W. van Dijk, Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels, Clin Exp Immunol 82 (1990), 579-582.
28. W. van Dijk, E.C. Havenaar and E.C. Brinkman-van der Linden, Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function, Glycoconj J 12 (1995), 227-233.
29. R.C. Bone, Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation, Crit Care Med 24 (1996), 163-172.
30. E.C. Brinkman-van der Linden, E.C. van Ommen and W. van Dijk, Glycosylation of alpha 1-acid glycoprotein in septic shock: changes in degree of branching and in expression of sialyl Lewis(x) groups, Glycoconj J 13 (1996), 27-31.
31. J. Deisenhofer, Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution, Biochemistry 20 (1981), 2361-2370.
32. P.M. Rudd, R.J. Leatherbarrow, T.W. Rademacher and R.A. Dwek, Diversification of the IgG molecule by oligosaccharides, Mol Immunol 28 (1991), 1369-1378.
33. P. Sondermann, J. Kaiser and U. Jacob, Molecular basis for immune complex recognition: a comparison of Fc-receptor structures, J Mol Biol 309 (2001), 737-749.
34. F. Nimmerjahn and J.V. Ravetch, Fcgamma receptors: old friends and new family members, Immunity 24 (2006), 19-28.
35. Y. Kaneko, F. Nimmerjahn and J.V. Ravetch, Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation, Science 313 (2006), 670-673.
36. P. Imbach, S. Barandun, V. d'Apuzzo, C. Baumgartner, A. Hirt, A. Morell, E. Rossi, M. Schoni, M. Vest and H.P. Wagner, High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood, Lancet 1 (1981), 1228-1231.
37. A. Samuelsson, T.L. Towers and J.V. Ravetch, Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor, Science 291 (2001), 484-486.
38. Y. Kaneko, F. Nimmerjahn, M.P. Madaio and J.V. Ravetch, Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors, J Exp Med 203 (2006), 789-797.
39. J.M. Dwyer, Manipulating the immune system with immune globulin, N Engl J Med 326 (1992), 107-116.
40. M.T. Goodarzi, J.S. Axford, S.S. Varanasi, A. Alavi, G. Cunnane, O. Fitzgerald and G.A. Turner, Sialyl Lewis(x) expression on IgG in rheumatoid arthritis and other arthritic conditions: a preliminary study, Glycoconj J 15 (1998), 1149-1154.
41. F.H. Routier, E.F. Hounsell, P.M. Rudd, N. Takahashi, A. Bond, F.C. Hay, A. Alavi, J.S. Axford and R. Jefferis, Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods, J Immunol Methods 213 (1998), 113-130.
42. J.S. Axford, Glycosylation and rheumatic disease, Biochim Biophys Acta 1455 (1999), 219-229.
43. A. Youings, S.C. Chang, R.A. Dwek and I.G. Scragg, Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients, Biochem J 314(Pt 2) (1996), 621-630.
44. R.B. Parekh, R.A. Dwek, B.J. Sutton, D.L. Fernandes, A. Leung, D. Stanworth, T.W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta et al., Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG, Nature 316 (1985), 452-457.
45. F. Nimmerjahn, R.M. Anthony and J.V. Ravetch, Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity, Proc Natl Acad Sci USA 104 (2007), 8433-8437.
46. C.T. Chou, Binding of rheumatoid and lupus synovial fluids and sera-derived human IgG rheumatoid factor to degalactosylated IgG, Arch Med Res 33 (2002), 541-544.
47. A. Young, N. Sumar, K. Bodman, S. Goyal, H. Sinclair, I. Roitt and D. Isenberg, Agalactosyl IgG: an aid to differential diagnosis in early synovitis, Arthritis Rheum 34 (1991), 1425-1429.
48. K. Bodman-Smith, N. Sumar, H. Sinclair, I. Roitt, D. Isenberg and A. Young, Agalactosyl IgG Gal(o)-an analysis of its clinical utility in the long-term follow-up of patients with rheumatoid arthritis, Br J Rheumatol 35 (1996), 1063-1066.
49. D. van Zeben, J.M. Hazes, A.H. Zwinderman, J.P. Vandenbroucke and F.C. Breedveld, The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset, J Rheumatol 21 (1994), 1620-1625.
50. D. van Zeben, G.A. Rook, J.M. Hazes, A.H. Zwinderman, Y. Zhang, S. Ghelani, T.W. Rademacher and F.C. Breedveld, Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study, Br J Rheumatol 33 (1994), 36-43.
51. A. Bond, A. Alavi, J.S. Axford, B.E. Bourke, F.E. Bruckner, M.A. Kerr, J.D. Maxwell, K.J. Tweed, M.J. Weldon, P. Youinou and F.C. Hay, A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine, J Autoimmun 10 (1997), 77-85.
52. R.B. Parekh, I.M. Roitt, D.A. Isenberg, R.A. Dwek, B.M. Ansell and T.W. Rademacher, Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity, Lancet 1 (1988), 966-969.
53. M. Flogel, G. Lauc, I. Gornik and B. Macek, Fucosylation and galactosylation of IgG heavy chains differ between acute and remission phases of juvenile chronic arthritis, Clin Chem Lab Med 36 (1998), 99-102.
54. M. Holland, K. Takada, T. Okumoto, N. Takahashi, K. Kato, D. Adu, A. Ben-Smith, L. Harper, C.O. Savage and R. Jefferis, Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis, Clin Exp Immunol 129 (2002), 183-190.
55. Y. Kuroda, M. Nakata, A. Makino, A. Matsumoto, K. Ohashi, K. Itahashi, F. Takeuchi, M. Goto, N. Kojima and T. Mizuochi, Structural studies on IgG oligosaccharides of patients with primary Sjogren's syndrome, Glycoconj J 19 (2002), 23-31.
56. A. Canellada and R.A. Margni, Modified immunoglobulin G glycosylation pattern during turpentine-induced acute inflammation in rats, Medicina (B Aires) 62 (2002), 249-255.
57. R. Parekh, I. Roitt, D. Isenberg, R. Dwek and T. Rademacher, Age-related galactosylation of the N-linked oligosaccharides of human serum IgG, J Exp Med 167 (1988), 1731-1736.
58. N. Sumar, K.B. Bodman, T.W. Rademacher, R.A. Dwek, P. Williams, R.B. Parekh, J. Edge, G.A. Rook, D.A. Isenberg, F.C. Hay et al., Analysis of glycosylation changes in IgG using lectins, J Immunol Methods 131 (1990), 127-136.
59. K. Shikata, T. Yasuda, F. Takeuchi, T. Konishi, M. Nakata and T. Mizuochi, Structural changes in the oligosaccharide moiety of human IgG with aging, Glycoconj J 15 (1998), 683-689.
60. G.A. Rook, J. Steele, R. Brealey, A. Whyte, D. Isenberg, N. Sumar, J.L. Nelson, K.B. Bodman, A. Young, I.M. Roitt et al., Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy, J Autoimmun 4 (1991), 779-794.
61. Y. Hitsumoto, S.J. Thompson, Y.W. Zhang, G.A. Rook and C.J. Elson, Relationship between interleukin 6, agalactosyl IgG and pristane-induced arthritis, Autoimmunity 11 (1992), 247-254.
62. S.J. Thompson, Y. Hitsumoto, Y.W. Zhang, G.A. Rook and C.J. Elson, Agalactosyl IgG in pristane-induced arthritis. Pregnancy affects the incidence and severity of arthritis and the glycosylation status of IgG, Clin Exp Immunol 89 (1992), 434-438.
63. A. Alavi, N. Arden, T.D. Spector and J.S. Axford, Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy, J Rheumatol 27 (2000), 1379-1385.
64. J. Feehally and A.C. Allen, Pathogenesis of IgA nephropathy, Ann Med Interne (Paris) 150 (1999), 91-98.
65. J. Barratt, A.C. Smith and J. Feehally, The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy, Nephrology (Carlton) 12 (2007), 275-284.
66. J. Feehally and A.C. Allen, Structural features of IgA molecules which contribute to IgA nephropathy, J Nephrol 12 (1999), 59-65.
67. G. de Jong, J.P. van Dijk and H.G. van Eijk, The biology of transferrin, Clin Chim Acta 190 (1990), 1-46.
68. K. Yamashita, N. Koide, T. Endo, Y. Iwaki and A. Kobata, Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma, J Biol Chem 264 (1989), 2415-2423.
69. K. Matsumoto, Y. Maeda, S. Kato and H. Yuki, Alteration of asparagine-linked glycosylation in serum transferrin of patients with hepatocellular carcinoma, Clin Chim Acta 224 (1994), 1-8.
70. L. Sturiale, R. Barone, A. Fiumara, M. Perez, M. Zaffanello, G. Sorge, L. Pavone, S. Tortorelli, J.F. O'Brien, J. Jaeken, and D. Garozzo, Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia, Glycobiology 15(2005),1268- 76.
71. M. Edwards, F. McKenzie, S. O'Callaghan, D. Somerset, P. Woodford, J. Spilsbury, M. Fietz and J. Fletcher, Prenatal diagnosis of congenital disorder of glycosylation type Ia (CDGIa) by cordocentesis and transferrin isoelectric focussing of serum of a 27-week fetus with non-immune hydrops, Prenat Diagn 26 (2006), 985-988.
72. T. Arndt, R. Hackler, T. Muller, T.O. Kleine and A.M. Gressner, Increased serum concentration of carbohydrate-deficient transferrin in patients with combined pancreas and kidney transplantation, Clin Chem 43 (1997), 344-351.
73. R.A. Feelders, G. Vreugdenhil, G. de Jong, A.J. Swaak and H.G. van Eijk, Transferrin microheterogeneity in rheumatoid arthritis. Relation with disease activity and anemia of chronic disease, Rheumatol Int 12 (1992), 195-199.
74. M. Grzymislawski, K. Derc, M. Sobieska and K. Wiktorowicz, Microheterogeneity of acute phase proteins in patients with ulcerative colitis, World J Gastroenterol 12 (2006), 5191-5195.
75. Y. Beguin, G. Bergamaschi, H.A. Huebers and C.A. Finch, The behavior of asialotransferrin-iron in the rat, Am J Hematol 29 (1988), 204-210.
76. J.R. Rudolph, E. Regoeczi, P.A. Chindemi and M.T. Debanne, Preferential hepatic uptake of iron from rat asialotransferrin: possible engagement of two receptors, Am J Physiol 251 (1986), G398-404.
77. M. Piagnerelli, K.Z. Boudjeltia, V. Nuyens, D. De Backer, F. Su, Z. Wang, J.L. Vincent and M. Vanhaeverbeek, Rapid alterations in transferrin sialylation during sepsis, Shock 24 (2005), 48-52.
78. G. de Jong and H.G. van Eijk, Microheterogeneity of human serum transferrin: a biological phenomenon studied by isoelectric focusing in immobilized pH gradients, Electrophoresis 9 (1988), 589-598.
79. R.F. Anton, Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. What have we learned? Where do we go from here? Alcohol 25 (2001), 185-188.
80. P. Konig, H. Niederhofer, H. Steurer, R. Haller, R. Wolfle, H. Fritzsche and P. Weiss, Changes of carbohydrate-deficient transferrin in chronic alcoholism, Neuropsychobiology 32 (1995), 192-196.
81. U. Nihlen, P. Montnemery, L.H. Lindholm and C.G. Lofdahl, Increased serum levels of carbohydrate-deficient transferrin in patients with chronic obstructive pulmonary disease, Scand J Clin Lab Invest 61 (2001), 341-347.
82. C.D. Spies, M. Kissner, T. Neumann, S. Blum, C. Voigt, T. Funk, N. Runkel and F. Pragst, Elevated carbohydrate-deficient transferrin predicts prolonged intensive care unit stay in traumatized men, Alcohol Alcohol 33 (1998), 661-669.
83. H. Stibler, Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed, Clin Chem 37 (1991), 2029-2037.
84. O. Gornik, I. Gornik, V. Gašparović and G. Lauc, Change in transferrin sialylation is a potential prognostic marker for severity of acute pancreatitis, Clin Biochem 41 (2008), 504-510.
85. S. Thompson, E. Dargan, I.D. Griffiths, C.A. Kelly and G.A. Turner, The glycosylation of haptoglobin in rheumatoid arthritis, Clin Chim Acta 220 (1993), 107-114.
86. A.C. Mann, S. Thompson, C.O. Record, C.H. Self and G.A. Turner, Monosaccharide composition of haptoglobin purified from alcoholic cirrhotic and control sera determined by HPAE, Biochem Soc Trans 21 (1993), 214S.
87. W. Chambers, S. Thompson, A.W. Skillen, C.O. Record and G.A. Turner, Abnormally fucosylated haptoglobin as a marker for alcoholic liver disease but not excessive alcohol consumption or non-alcoholic liver disease, Clin Chim Acta 219 (1993), 177-182.
88. A.C. Mann, C.O. Record, C.H. Self and G.A. Turner, Monosaccharide composition of haptoglobin in liver diseases and alcohol abuse: large changes in glycosylation associated with alcoholic liver disease, Clin Chim Acta 227 (1994), 69-78.
89. C. Panzironi, B. Silvestrini, M.Y. Mo, R. Lahita, D. Mruk and C.Y. Cheng, An increase in the carbohydrate moiety of alpha 2-macroglobulin is associated with systemic lupus erythematosus (SLE), Biochem Mol Biol Int 43 (1997), 1305-1322.
90. N. Cazzolla, L. Saso, J. Grima, M.G. Leone, E. Grippa, C.Y. Cheng and B. Silvestrini, Development of an enzyme-linked immunosorbent assay, using a monoclonal antibody against alpha2-macroglobulin, for the diagnosis of systemic lupus erythematosus, Clin Biochem 32 (1999), 249-255.
91. T. Das, A.K. Sen, T. Kempf, S.R. Pramanik, C. Mandal and C. Mandal, Induction of glycosylation in human C-reactive protein under different pathological conditions, Biochem J 373 (2003), 345-355.
92. T. Das, C. Mandal and C. Mandal, Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions, Glycoconj J 20 (2004), 537-543.
93. P. Sillanaukee, M. Ponnio and I.P. Jaaskelainen, Occurrence of sialic acid s in healthy humans and different disorders, Eur J Clin Invest 29 (1999), 413-425.
94. Z. Yasukawa, C. Sato and K. Kitajima, Inflammation-dependent changes in alpha2,3-, alpha2,6-, and alpha2,8-sialic acid glycotopes on serum glycoproteins in mice, Glycobiology 15 (2005), 827-837.
95. M.M. Chavan, P.D. Kawle and N.G. Mehta, Increased sialylation and defucosylation of plasma proteins are early events in the acute phase response, Glycobiology 15 (2005), 838-848.
96. L. Saso, G. Valentini, A.M. Giardino, A. Spadaro, V. Riccieri, A. Zoppini and B. Silvestrini, Changes of glycosylation of serum proteins in psoriatic arthritis, studied by enzyme-linked lectin assay (ELLA), using concanavalin A, Biochem Mol Biol Int 46 (1998), 867-875.
97. K. Fassbender, B. Gerber, U. Karrer, M. Sobieska, A. Aeschlimann and W. Muller, Glycosylation of acute phase proteins and interleukins following hip arthroplasty. Inflammation parameters studied in 10 patients, Acta Orthop Scand 64 (1993), 216-220.
98. L. Royle, C.M. Radcliffe, R.A. Dwek and P.M. Rudd, Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions, Methods Mol Biol 347 (2006), 125-143.
99. E. Llop, R.G. Gallego, V. Belalcazar, G.J. Gerwig, J.P. Kamerling, J. Segura and J.A. Pascual, Evaluation of protein N-glycosylation in 2-DE: Erythropoietin as a study case, Proteomics (2007).
100. N. Itoh, S. Sakaue, H. Nakagawa, M. Kurogochi, H. Ohira, K. Deguchi, S. Nishimura and M. Nishimura, Analysis of Nglycan in serum glycoproteins from db/db mice and humans with type 2 diabetes, Am J Physiol Endocrinol Metab 293 (2007), E1069-1077.
101. W. Morelle, C. Flahaut, J.C. Michalski, A. Louvet, P. Mathurin and A. Klein, Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis, Glycobiology 16 (2006), 281-293.
102. O. Gornik, L. Royle, D.J. Harvey, C.M. Radcliffe, R. Saldova, R.A. Dwek, P. Rudd and G. Lauc, Changes of serum glycans during sepsis and acute pancreatitis, Glycobiology 17 (2007), 1321-1332.